1.6.5.2: NAD(P)H dehydrogenase (quinone)

This is an abbreviated version!
For detailed information about NAD(P)H dehydrogenase (quinone), go to the full flat file.

Word Map on EC 1.6.5.2

Reaction

NAD(P)H
+
H+
+
a quinone
=
NAD(P)+
+
a hydroquinone

Synonyms

1,4-benzoquinone reductase, azoreductase, chromate reductase, ChrR, dehydrogenase, reduced nicotinamide adenine dinucleotide (phosphate, quinone), diaphorase, DPND, DPNH-diaphorase, DT-diaphorase, DTD, DVU_2399, DVU_2400, DVU_2401, EC 1.6.99.2, FerB, ferric reductase B, flavoprotein NAD(P)H-quinone reductase, FlxABCD, FMN-dependent NAD(P)H:quinone oxidoreductase, Internal NADH dehydrogenase, MdaB, Menadione oxidoreductase, Menadione reductase, NAD(P)H dehydrogenase, NAD(P)H dehydrogenase complex, NAD(P)H menadione reductase, NAD(P)H quinone oxidoreductase, NAD(P)H quinone oxidoreductase-1, NAD(P)H quinone oxidoreductase1, NAD(P)H quinone reductase, NAD(P)H quinone-oxidoreductase 1, NAD(P)H-QR, NAD(P)H-quinone dehydrogenase, NAD(P)H-quinone oxidoreductase, NAD(P)H: (quinone acceptor) oxidoreductase, NAD(P)H: (quinone-acceptor)oxidoreductase, NAD(P)H: menadione oxidoreductase, NAD(P)H: Quinone oxidoreductase, NAD(P)H: quinone oxidoreductase 1, NAD(P)H: quinone oxidoreductase-1, NAD(P)H: quinone reductase, NAD(P)H:acceptor oxidoreductase, NAD(P)H:quinone acceptor oxidoreductase, NAD(P)H:quinone oxidoreducatase 1, NAD(P)H:quinone oxidoreductase, NAD(P)H:quinone oxidoreductase 1, NAD(P)H:quinone oxidoreductase I, NAD(P)H:quinone oxidoreductase-1, NAD(P)H:quinone reductase, NAD(P)H:quinoneoxidoreductase 1, NADH-menadione reductase, NADH:quinone oxidoreductase 1, NADPH quinone reductase, NADPH: quinone oxidoreductase-1, NADPH:quinone oxidoreductase, NADPH:quinone oxidoreductase 1, NAD[P]H:quinone acceptor oxidoreductase 1, Naphthoquinone reductase, Ndh complex, NDH2, nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1, NQO1, NQR, NRH:quinone reductase 1, p-Benzoquinone reductase, Pden_4071, PfNdh2, Phylloquinone reductase, QOR2, QR1, QR2, Quinone reductase, quinone reductase 1, quinone reductase type 1, Reduced NAD(P)H dehydrogenase, reduced nicotinamide-adenine dinucleotide (phosphate) dehydrogenase, TcpB, TmQR2, type II NADH: quinone oxidoreductase, Viologen accepting pyridine nucleotide oxidoreductase, Vitamin K reductase, vitamin-K reductase, WrbA

ECTree

     1 Oxidoreductases
         1.6 Acting on NADH or NADPH
             1.6.5 With a quinone or similar compound as acceptor
                1.6.5.2 NAD(P)H dehydrogenase (quinone)

Inhibitors

Inhibitors on EC 1.6.5.2 - NAD(P)H dehydrogenase (quinone)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(A)-2-Azido-NAD+
-
photodependent inhibition
(A)-8-azido-NAD+
-
photodependent inhibition
1,10-phenanthroline
1,4-diaminoanthraquinone-2-sulfonic acid
-
-
1,4-Naphthohydroquinone
-
competitive vs. 1,4-naphthohydroquinone, noncompetitive vs. NADPH
1-amino-4-[(3-carboxyphenyl)amino]-anthraquinone-2-sulfonic acid
-
-
1-amino-4-[(4-amino-3-sulfophenyl)amino]-anthraquinone-2-sulfonic acid
-
-
1-aminoanthraquinone
-
-
1-aminoanthraquinone-2-carboxylic acid
-
-
1-hydroxy-2-(1-naphthylmethyl)-3H-benzo[f]chromen-3-one
-
-
1-hydroxy-2-(2-naphthylmethyl)-3H-benzo[f]chromen-3-one
-
-
1-hydroxy-2-dodecyl-4(1H)-quinolone
-
-
1-hydroxy-2-dodecyl-4(1H)quinolone
-
-
1-hydroxy-2-octyl-4(1H)quinolone
-
-
1-hydroxy-2-[2-(nitrooxy)ethyl]-1-oxo-2-(2,4,6-trinitro-3-(nitro[2-(nitrooxy)ethyl]amino)phenyl)diazanium
-
competitive
1-[3,5-dinitro-2-(1,2,3,4-tetrahydronaphthalen-2-yl)phenyl]-1-oxohydrazinium
-
-
10-nitro-5,6-dihydrobenzimidazo[2,1-a]isoquinoline 12-oxide
-
-
10-nitro-5,6-dihydrobenzimidazo[2,1-a]isoquinoline-8-carboxamide 12-oxide
-
-
10-nitro-5,6-dihydrobenzimidazo[2,1-a]isoquinoline-9-carboxamide 12-oxide
-
-
2,10-dinitro-5,6-dihydrobenzimidazo[2,1-a]isoquinoline 12-oxide
-
-
2,2'-dimethoxy-trans-stilbene
2,4'-dimethoxy-cis-stilbene
2,4'-dimethoxy-trans-stilbene
2,4,4'-trimethoxy-cis-stilbene
2,4,4'-trimethoxy-trans-stilbene
2,4,6-trinitrotoluene
-
competitive
2,4-dinitro-5-(1,2,3,4-tetrahydronaphthalen-2-yl)benzamide
-
-
2,4-dinitro-5-(5-nitro-1,2,3,4-tetrahydronaphthalen-2-yl)benzamide
-
-
2,4-dinitro-5-(7-nitro-1,2,3,4-tetrahydronaphthalen-2-yl)benzamide
-
-
2,4-Dinitroaniline
-
0.1 mM, 33% inhibition
2,4-Dinitronaphthol
-
0.1 mM, 90% inhibition
2,4-dinitrophenol
2,6,4'-trimethoxy-trans-stilbene
2-(2,4,6-trinitrophenyl)-1,2,3,4-tetrahydronaphthalene
-
-
2-(2,4-dinitrophenyl)-1,2,3,4-tetrahydronaphthalene
-
-
2-(2,4-dinitrophenyl)-5-nitro-1,2,3,4-tetrahydronaphthalene
-
-
2-(2,4-dinitrophenyl)-7-nitro-1,2,3,4-tetrahydronaphthalene
-
-
2-(4'-chlorophenyl)-indan-1,3-dione
-
0.0002 mM, 50% inhibition
2-benzyl-1-hydroxy-3H-benzo[f]chromen-3-one
-
-
2-Heptyl-4-hydroxyquinoline-N-oxide
-
-
2-hydroxy-4'-methoxy-trans-stilbene
2-Pivaloyl-1,3-indanedione
-
-
2-[2,4-dinitro-6-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydronaphthalene
-
-
2-[2,4-dinitro-6-(trifluoromethyl)phenyl]-5-nitro-1,2,3,4-tetrahydronaphthalene
-
-
2-[2,4-dinitro-6-(trifluoromethyl)phenyl]-7-nitro-1,2,3,4-tetrahydronaphthalene
-
-
2-[nitro(2,4,6-trinitrophenyl)amino]ethyl nitrate
-
competitive
3,3'-(9H-fluoren-3-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(biphenyl-4-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(furan-2-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(naphthalen-2-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(phenylmethanediyl)bis(4,7-dihydroxy-2H-chromen-2-one)
-
-
3,3'-(phenylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(pyridin-2-ylmethanediyl)bis(4,7-dihydroxy-2H-chromen-2-one)
-
-
3,3'-(quinolin-3-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(thiophen-2-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-([4-[(E)-2-phenylethenyl]phenyl]methanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-butane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4,7-dihydroxy-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-2H-benzo[h]chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-5-methoxy-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-6,7-dimethoxy-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-6,7-dimethyl-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-6,8-dibromo-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-6-chloro-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-6-fluoro-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-6-methoxy-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-7,8-dimethyl-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-7-fluoro-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-7-methoxy-2H-chromen-2-one)
-
-
3,3'-methylene-bis(4-hydroxycoumarin)
3,3'-methylenebis(4-hydroxy-6-methyl-2H-chromen-2-one)
-
-
3,3'-[(4-chlorophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-hydroxy-3-methoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-hydroxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-methoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[[3,5-bis(benzyloxy)phenyl]methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[[4-(1-methylethyl)phenyl]methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[[4-(dimethylamino)phenyl]methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,4'-dimethoxy-cis-stilbene
3,4'-dimethoxy-trans-stilbene
-
-
3,4,4'-trimethoxy-cis-stilbene
3,4,4'-trimethoxy-trans-stilbene
3,4,5,4'-tetramethoxy-cis-stilbene
3,4,5,4'-tetramethoxy-trans-stilbene
3,5,4'-trimethoxy-cis-stilbene
3,5,4'-trimethoxy-trans-stilbene
3,5-dihydroxy-4'-methoxy-cis-stilbene
3,5-dihydroxy-4'-methoxy-trans-stilbene
3,5-dinitro-2-(1,2,3,4-tetrahydronaphthalen-2-yl)benzamide
-
-
3,5-dinitro-2-(1,2,3,4-tetrahydronaphthalen-2-yl)benzoic acid
-
-
3,5-dinitro-2-(5-nitro-1,2,3,4-tetrahydronaphthalen-2-yl)benzoic acid
-
-
3,5-dinitro-2-(7-nitro-1,2,3,4-tetrahydronaphthalen-2-yl)benzoic acid
-
-
3-(2,4-difluorophenoxymethyl)-6-methoxy-1,2-dimethylindole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells
3-(2-fluoro-4-nitrophenoxymethyl)-5-methoxy-1,2-dimethylindole-4,7-dione
-
-
3-(2-fluoro-4-nitrophenoxymethyl)-6-methoxy-1,2-dimethylindole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells
3-(3,4-dimethylbenzyl)-4-hydroxy-2H-chromen-2-one
-
-
3-(3,4-dimethylbenzyl)-4-hydroxy-6,7-dimethyl-2H-chromen-2-one
-
-
3-(4-aminophenoxymethyl)-6-methoxy-1,2-dimethylindole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells
3-(4-cyanophenoxymethyl)-6-methoxy-1,2-dimethylindole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells; indolequinone derivative 22, dose dependent inhibition of NQO1 activity in MiaPaCa-2
3-(4-fluorophenoxymethyl)-6-methoxy-1,2-dimethylindole-4,7-dione
-
indolequinone derivative 24, dose dependent inhibition of NQO1 activity in MiaPaCa-2
3-(alpha-phenylpropyl)-4-hydroxycoumarin
-
0.01 mM, 50% inhibition
3-([[4-Iodophenyl]thio]methyl)-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione
-
compound based on the selective binding of indolequinone analogs to the active site of NQO1 by the stacking effect. [125]I-marked compound can be used as an internal radiation agent for the treatment of cancer
-
3-benzyl-4-hydroxy-2H-benzo[h]chromen-2-one
-
-
3-benzyl-4-hydroxy-2H-chromen-2-one
-
-
3-benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one
-
-
3-hydroxy-4'-methoxy-cis-stilbene
3-hydroxy-4'-methoxy-trans-stilbene
3-hydroxy-4,4'-dimethoxy-cis-stilbene
3-hydroxy-4,4'-dimethoxy-trans-stilbene
3-methoxy-1,2-dimethyl-3-(3-pyridyloxymethyl)indole-4,7-dione
-
-
3-[alpha-(4'-nitrophenyl)-beta-acetylethyl]-4-hydroxycoumarin
-
0.02 mM, 50% inhibition
3-[[3-[bis(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]phenyl](4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)methyl]-4-hydroxy-2H-chromen-2-one
-
-
3-[[4-[bis(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]phenyl](4,7-dihydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)methyl]-4,7-dihydroxy-2H-chromen-2-one
-
-
3-[[4-[bis(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]phenyl](4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)methyl]-4-hydroxy-2H-chromen-2-one
-
-
4',5,7-trihydroxyflavone
-
0.01 mM, 61% inhibition, recombinant NAD(P)H:quinone acceptor oxidoreductase 2
4,10-dinitro-5,6-dihydrobenzimidazo[2,1-a]isoquinoline 12-oxide
-
-
4,10-dinitro-5,6-dihydrobenzimidazo[2,1-a]isoquinoline-9-carboxamide 12-oxide
-
-
4,10-dinitro-8-(trifluoromethyl)-5,6-dihydrobenzimidazo[2,1-a]isoquinoline 12-oxide
-
-
4,4'-dichlorodicoumarol
-
0.001 mM, 50% inhibition
4,4'-dimethoxy-cis-stilbene
4,4'-dimethoxy-trans-stilbene
4,5,6,7-tetranitro-1,3-dihydro-2H-benzimidazol-2-one
-
competitive
4,5,6-trinitro-1,3-dihydro-2H-benzimidazol-2-one
-
competitive
4-amino-2H-chromen-2-one
-
-
4-chloromercuribenzoate
-
74% residual activity at 0.15 mM
4-hydroxy-3-(1-naphthylmethyl)-2H-benzo[h]chromen-2-one
-
-
4-hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one
-
-
4-hydroxy-3-(2-naphthylmethyl)-2H-benzo[h]chromen-2-one
-
-
4-hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one
-
-
4-hydroxy-3-(naphthalen-1-yl)cyclohepta[h]chromen-2(7H)-one
-
-
4-hydroxy-3-(naphthalen-2-yl)cyclohepta[h]chromen-2(7H)-one
-
-
4-hydroxy-3-phenylcyclohepta[h]chromen-2(7H)-one
-
-
4-hydroxy-3-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-2H-1-benzopyran-2-one
-
10 microM, 89.2% inhibition. At 0.0084 microM, 50% toxicity in A549 cells in the presence of 20 mM beta-lapachone. Inhibitor is used to built a functional affinity-based small-molecule fluoresent probe composed of the NQO1 inhibitor as the recognition group, a linker and the fluorophores group FITC
-
4-hydroxy-6,7-dimethyl-3-(1-naphthylmethyl)-2H-chromen-2-one
-
-
4-hydroxy-6,7-dimethyl-3-(2-naphthylmethyl)-2H-chromen-2-one
-
-
4-hydroxy-6,7-dimethyl-3-(naphthalen-1-yl)-2H-chromen-2-one
-
-
4-hydroxy-6,7-dimethyl-3-(naphthalen-2-yl)-2H-chromen-2-one
-
-
4-hydroxy-6,7-dimethyl-3-phenyl-2H-chromen-2-one
-
-
4-Hydroxycoumarin
-
-
4-hydroxymercuribenzoate
-
0.067 mM, 50% inhibition
4-Methoxycoumarin
-
-
4-[bis(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]benzoic acid
-
-
5,5'-dithiobis(2-nitrobenzoic acid)
5,6-dimethylxanthenone-4-acetic acid
-
tumour blood flow inhibitor, competitive vs. NADH
5,7-dihydroxyflavone
5-hydroxy-7-bromoacetylflavone
-
0.00018 mM, 50% inhibition, irreversible, useful as affinity label
5-methoxy-1,2-dimethyl-3-(2,4,6-trifluorophenoxymethyl)indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells; indolequinone derivative 10, mechanism based 80% inhibition
5-methoxy-1,2-dimethyl-3-(2-nitrophenoxymethyl)indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells
5-methoxy-1,2-dimethyl-3-(3-nitrophenoxymethyl)indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCaa-2 cells; indolequinone derivative 6, dose dependent inhibition of NQO1 activity in MiaPaCa-2
5-methoxy-1,2-dimethyl-3-(3-pyridyloxymethyl)indole-4,7-dione
-
indolequinone derivative 12, dose dependent inhibition of NQO1 activity in MiaPaCa-2
5-methoxy-1,2-dimethyl-3-(4-nitrophenoxymethyl)indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells
5-methoxy-1,2-dimethyl-3-(phenoxymethyl)indole-4,7-dione
-
-
5-methoxy-1,2-dimethyl-3-(pyridin-2-yloxymethyl)indole-4,7-dione
-
indolequinone derivative 11, mechanism based 90% inhibition
5-methoxy-1,2-dimethyl-3-(pyridin-4-yloxymethyl)indole-4,7-dione
-
-
5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]-indole-4,7-dione
-
ES936, potent mechanism-based inhibitor of NQO1, complete inhibition at 0.001 mM
5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione
5-methoxy-1,2-dimethyl-3-[(4-pyridinyloxy)methyl]indole-4,7-dione
-
approximately 90% inhibition of enzyme activity after 4 h, and this inactivation is dependent upon NADH
5-methoxy-1,2-dimethyl-3-[1-(4-nitrophenoxy)ethyl]indole-4,7-dione
-
-
5-methoxy-1,2-dimethyl-[(4-nitrophenoxy)methyl]indole-4,7-dione
6-methoxy-1,2-dimethyl-3-(2,4,6-trifluorophenoxymethyl)indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells; indolequinone derivative 26, mechanism based 90% inhibition
6-methoxy-1,2-dimethyl-3-(2-nitrophenoxymethyl)indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCaa-2 cells
6-methoxy-1,2-dimethyl-3-(3-nitrophenoxymethyl)indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells
6-methoxy-1,2-dimethyl-3-(4-nitrophenoxymethyl)indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells; indolequinone derivative 15, mechanism based 85% inhibition
6-methoxy-1,2-dimethyl-3-(phenoxymethyl)indole-4,7-dione
-
-
6-methoxy-1,2-dimethyl-3-(pyridin-2-yloxymethyl)indole-4,7-dione
-
indolequinone derivative 27, mechanism based 90% inhibition
6-methoxy-1,2-dimethyl-3-(pyridin-4-yloxymethyl)indole-4,7-dione
-
indolequinone derivative 29, mechanism based 95% inhibition
6-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione
-
approximately 90% inhibition of enzyme activity after 4 h, and this inactivation is dependent upon NADH
6-methoxy-1,2-dimethyl-3-[(4-pyridinyloxy)methyl]indole-4,7-dione
-
approximately 90% inhibition of enzyme activity after 4 h, and this inactivation is dependent upon NADH
6-methoxy-1,2-dimethyl-3-[(acetoxy)methyl]indole-4,7-dione
-
approximately 90% inhibition of enzyme activity after 4 h, and this inactivation is dependent upon NADH
6-methoxy-1,2-dimethyl-3-[2-nitrophenoxymethyl]indole-4,7-dione
-
indolequinone derivative 19, mechanism based 95% inhibition, dose dependent inhibition of NQO1 activity in MiaPaCa-2
6-methoxy-1,2-dimethyl-3-[4-(trifluoromethyl)phenoxymethyl]-indole-4,7-dione
-
effective inhibitor of the growth of MiaPaCa-2 cells; indolequinone derivative 23, dose dependent inhibition of NQO1 activity in MiaPaCa-2
7,8-dibromoacetylflavone
-
0.00003 mM, 50% inhibition
7,8-dihydroxyflavone
-
-
7-(4-hydroxy-2-oxo-2H-chromen-3-yl)-6a,7-dihydro-4aH,6H,8H-pyrano[3,2-c:5,6-c']dichromene-6,8-dione
-
-
7-(4-hydroxy-2-oxo-2H-chromen-3-yl)-6H,7H-chromeno[4,3-b]chromen-6-one
-
-
7-bromoacetylflavone
-
time-dependent inactivation within 30 s, 0.00074 mM, 50% inhibition
7-hydroxyflavone
-
-
7-hydroxylflavone
-
competitive inhibition, 0.00074 mM, 50% inhibition
7-N-acetyldemethyllavendamycin n-butyl amide
lavendamycin analogue 12, selective toxic toward NQO1-rich cells
8-hydroxyquinoline
-
1 mM, 50% inhibition
acid blue 25
-
-
ADP
-
86% residual activity at 0.2 mM
Alizarin Red S
-
0.04 mM, 38% inhibition
alpha,alpha'-dipyridyl
-
IC50: 1 mM
alpha-naphthoflavone
-
0.01 mM, 75% inhibition, recombinant NAD(P)H:quinone acceptor oxidoreductase 2
Amytal
-
6.6 mM, 55% inhibition
anthraquinone
-
-
anthraquinone-2-carboxylic acid
-
-
anthraquinone-2-sulfonic acid
-
-
ATP
-
91% residual activity at 0.2 mM
benzoquinol
-
shows noncompetitive inhibition in all conditions, it can bind to multiple enzyme forms or sites, even when either of the substrates (NADH or benzoquinone) is present at high concentrations
beta-naphthoflavone
-
0.01 mM, 76% inhibition, recombinant NAD(P)H:quinone acceptor oxidoreductase 2
bromaminic acid
-
-
capsaicin
-
activity is decreased after the treatment with capsaicin or dicoumarol. Quinone metabolites or other reactive forms of capsaicin may bind covalently to NQO1 and thereby inhibit its activity, leading to production of reactive oxygen species; suppresses NQO1 expression and activity. Quinone metabolites or other reactive forms of capsaicin may bind covalently to NQO1 and thereby inhibit its activity, leading to production of reactive oxygen species
chrysin
Cibacron blue
Cibacron Blue F3G-A
-
0.04 mM, 75% inhibition
cis-stilbene
-
-
Cr6+
-
decrease of enzyme mRNA level together with heme oxygenase-1 and glutathione S-transferase Ya
Cu2+
-
decrease of enzyme mRNA expression, via a transcriptional mechanism
curcumin
-
inhibition of enzyme activity in vivo and in vitro. Inducues dissociation of complexes of enzyme with tumor suppressor protein p53 leading to degradation of p53, but not of p53 cancer hot-spot mutant R273H
dicoumarol
Dicoumarol dimethylether
-
0.0005, 50% inhibition
dicumarol
diphenylene iodonium chloride
-
-
EGTA
-
95% residual activity at 5 mM
ES 936
-
-
ES936
ethyl 5-aziridin-1-yl-2,4-dinitrobenzoate
-
competitive
ethyl bis(2-hydroxy-4-oxo-4H-chromen-3-yl)acetate
ethyl bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate
-
-
flavone-8-acetic acid
-
tumour blood flow inhibitor, competitive vs. NADH
galangin
-
0.01 mM, 100% inhibition, recombinant NAD(P)H:quinone acceptor oxidoreductase 2
HgCl2
-
0.2 mM, 94% inhibition
hydroxy(oxo)(3,6,8-trinitro-9H-carbazol-1-yl)ammonium
-
competitive
iodoacetic acid
-
-
isorhamnetin
-
-
lavendamycin beta-hydroxyethyl ester
lavendamycin analogue 12, selective toxic toward NQO1-rich cells
Mersalyl
-
68% residual activity at 0.15 mM
methylene-5,5'-bis(4,6-dioxo-2-methyldihydropyran)
-
0.003 mM, 50% inhibition
mitomycin C
morin
-
0.01 mM, 95% inhibition, recombinant NAD(P)H:quinone acceptor oxidoreductase 2
N-ethyl maleimide
-
0.33 mM, complete inhibition
N-ethylmaleimide
-
-
N-methyl-N,2,4,6-tetranitroaniline
-
competitive
N-methyl-N,2,4-trinitroaniline
-
competitive
NADP+
nitracrine
-
competitive
p-chloromercuribenzoate
-
-
Phenindione
-
0.1 mM, 92% inhibition
phenylmercuric acetate
-
-
pinosylvin
-
-
Procion blue M-3GS
-
-
Procion blue MX-R
-
0.04 mM, 75% inhibition
quercetin
quinacrine dihydrochloride
-
0.05 mM, 65-95% inhibition depending on substrate
reserpine
-
competitive inhibitor of DT-diaphorase
resveratrol
salicylate
-
1 mM, 62% inhibition
siRNA
-
siRNA for NQO1 inhibits clonogenic cell death caused by beta-lap
-
SOD
-
inhibits the NADPH:chromate reductase reaction of NQO1
-
Thenoyltrifluoroacetone
-
-
trans-stilbene
-
-
vitamin E
-
-
warfarin
-
1 mM, 70% inhibition
additional information
-